Orion Portfolio Solutions LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 10.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,840 shares of the biopharmaceutical company’s stock after buying an additional 7,119 shares during the period. Orion Portfolio Solutions LLC’s holdings in Pfizer were worth $4,030,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ullmann Wealth Partners Group LLC increased its holdings in Pfizer by 6.2% in the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 335 shares in the last quarter. Red Door Wealth Management LLC grew its stake in shares of Pfizer by 8.6% in the first quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company’s stock valued at $5,675,000 after buying an additional 8,694 shares in the last quarter. Capital City Trust Co. FL raised its holdings in shares of Pfizer by 49.9% during the 1st quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 2,816 shares during the period. Colonial River Wealth Management LLC lifted its position in Pfizer by 52.3% during the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company’s stock worth $1,087,000 after acquiring an additional 7,206 shares in the last quarter. Finally, Annex Advisory Services LLC boosted its holdings in Pfizer by 23.6% in the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company’s stock worth $532,000 after acquiring an additional 1,966 shares during the period. Institutional investors and hedge funds own 67.90% of the company’s stock.
Analysts Set New Price Targets
A number of research analysts have recently commented on PFE shares. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research report on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price objective on shares of Pfizer in a research report on Thursday, September 1st. Barclays set a $50.00 price target on Pfizer in a research note on Thursday, September 1st. SVB Leerink lowered their price objective on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research note on Friday, July 29th. Finally, Morgan Stanley cut their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research report on Friday, July 8th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $57.00.
Pfizer Trading Down 0.1 %
Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The firm had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer’s revenue was up 46.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.07 EPS. As a group, research analysts expect that Pfizer Inc. will post 6.54 EPS for the current year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.47%. The ex-dividend date was Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is presently 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.